Z
Zhi-Xu He
Researcher at Guiyang Medical University
Publications - 6
Citations - 651
Zhi-Xu He is an academic researcher from Guiyang Medical University. The author has contributed to research in topics: Bardoxolone methyl & IκB kinase. The author has an hindex of 6, co-authored 6 publications receiving 517 citations.
Papers
More filters
Journal ArticleDOI
Molecular mechanisms for tumour resistance to chemotherapy.
TL;DR: This review highlights the current knowledge of the role of altered drug metabolism and transport and deregulation of apoptosis and autophagy in the development of tumour chemoresistance and indicates that deregulation of programmed cell death including apoptotic death is also an important mechanism for tumour resistance to anticancer drugs.
Journal ArticleDOI
Bardoxolone methyl (CDDO-Me) as a therapeutic agent: an update on its pharmacokinetic and pharmacodynamic properties.
TL;DR: As a multifunctional agent, CDDO-Me has improved the renal function in patients with chronic kidney disease associated with type 2 diabetes and has shown a promising anticancer effect in a Phase I trial.
Journal ArticleDOI
Plumbagin induces G2/M arrest, apoptosis, and autophagy via p38 MAPK- and PI3K/Akt/mTOR-mediated pathways in human tongue squamous cell carcinoma cells
Shu-Ting Pan,Yiru Qin,Zhi Wei Zhou,Zhi-Xu He,Xueji Zhang,Tianxin Yang,Yinxue Yang,Dong Wang,Jia-Xuan Qiu,Shu-Feng Zhou +9 more
TL;DR: The results indicate that PLB promotes cellular apoptosis and autophagy in TSCC cells involving p38 MAPK- and PI3K/Akt/mTOR- mediated pathways with contribution from the GSK3β and ROS-mediated pathways.
Journal ArticleDOI
An update on the pharmacokinetics and pharmacodynamics of alisertib, a selective Aurora kinase A inhibitor.
TL;DR: Alisertib is one selective AURKA inhibitor that has shown remarkable anticancer effects in preclinical studies and is a new promising anticancer therapy and further mechanistic and clinical studies are warranted.
Journal ArticleDOI
Therapeutic effects of C-28 methyl ester of 2-cyano-3,12-dioxoolean-1,9-dien-28-oic acid (CDDO-Me; bardoxolone methyl) on radiation-induced lung inflammation and fibrosis in mice.
TL;DR: Findings suggest that CDDO-Me ameliorates radiation-induced lung inflammation and fibrosis, and this synthetic triterpenoid is a promising novel therapeutic agent for RILI.